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Drug screening of biopsy-derived 
spheroids using a self-generated 
microfluidic concentration gradient
Theresa Mulholland1, Milly McAllister2, Samantha Patek2, David Flint3, Mark Underwood4, 
Alexander Sim5, Joanne Edwards  2 & Michele Zagnoni 1
Performing drug screening of tissue derived from cancer patient biopsies using physiologically relevant 
3D tumour models presents challenges due to the limited amount of available cell material. Here, 
we present a microfluidic platform that enables drug screening of cancer cell-enriched multicellular 
spheroids derived from tumour biopsies, allowing extensive anticancer compound screening prior 
to treatment. This technology was validated using cell lines and then used to screen primary human 
prostate cancer cells, grown in 3D as a heterogeneous culture from biopsy-derived tissue. The 
technology enabled the formation of repeatable drug concentration gradients across an array of 
spheroids without external fluid actuation, delivering simultaneously a range of drug concentrations 
to multiple sized spheroids, as well as replicates for each concentration. As proof-of-concept screening, 
spheroids were generated from two patient biopsies and a panel of standard-of-care compounds for 
prostate cancer were tested. Brightfield and fluorescence images were analysed to provide readouts of 
spheroid growth and health, as well as drug efficacy over time. Overall, this technology could prove a 
useful tool for personalised medicine and future drug development, with the potential to provide cost- 
and time-reduction in the healthcare delivery.
Over the last 10 years, the use of three-dimensional (3D) cell culture models and consideration of the extracel-
lular microenvironment have been shown to be of immense importance when studying cancer therapies and the 
mechanisms leading to drug resistance and metastasis1–3. Cell signalling, cell-to-cell contact, chemical and gas 
concentration gradients are altered in two-dimensional (2D) cultures with respect to the 3D in vivo microenvi-
ronment4. These differences can affect mechanistic studies, but especially drug screening, where cells can be more 
or less sensitive in 3D than in 2D, or even completely resistant5, depending on the drug’s mechanism of action6,7. 
Furthermore, 2D culture neglects the presence of varying degrees of cellular metabolic activity, typical of in vivo 
tumours3,4. Recently, the drive to create more refined in vitro 3D tumour models, which mimic the heterogeneous 
human tumour microenvironment, has resulted in the use of human tumour tissue for the generation of multicel-
lular spheroids8. Animal-based methods, such as patient-derived xenografts (PDX) and PDX-derived spheroids, 
offer increased physiological relevance and are superior to in vitro models for the study of malignant transfor-
mation, invasion and metastasis. However, the compromised immune system of the host mice and the lack of 
human stromal tissue are reasons for their poor predictive value9–11. Conventional methods used for the gener-
ation spheroids, such as spinner flask, forced-floating and hanging drop techniques4,12,13 offer the opportunity 
for high-throughput screening. Other advanced techniques utilise scaffolds, magnetically levitate spheroids or 
use aqueous biphasic microtechnology for the generation and culture of spheroids14,15. However, these methods 
have the disadvantage of requiring relatively large volumes of reagents and cellular material4, which is a particular 
challenge when working with biopsy-derived tumour tissue8.
Microfluidic technologies have increasingly been used for spheroid-based assays and offer viable solutions 
when working with biopsy-derived tumour tissue, providing precise control over the cellular microenvironment, 
3D cell culture and medium- to high-throughput readouts in a cost-effective manner16–19. Importantly, laminar 
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flow conditions enable the formation of compound concentration gradients, leading to multiple experimental 
conditions to be tested simultaneously within a micro-scale device. A variety of designs have been proposed, 
relying on T-junction gradient generators and tree-like microfluidic structures, which have been adapted for 
chemotaxis investigation and drug testing20,21. However, a common disadvantage of all these approaches is that 
they typically require external instrumentation for fluid actuation, such as syringe pumps or pressure controllers, 
and multiple tubes to be connected to the device. These can be bulky, expensive and hinder the ease of use of 
microfluidic technology in research and industrial environments. Alternative approaches have been proposed to 
generate stable concentration gradients without the use of external equipment22, but until now this has not been 
applied to spheroid-based drug screening.
Here, we present a microfluidic platform and associated cell culture protocols, aimed to facilitate extensive 
screening of cancer cell-enriched multicellular spheroids derived from human tumour biopsies. Novel aspects of 
our microfluidic design include self-generating perfusion of nutrients and repeatable, long-lasting drug concen-
tration gradients across an array of hundreds of spheroids without requiring equipment to be connected to the 
device for fluid actuation. Using this system, several concentration response curves (8-point curves obtained from 
a starting sample of ~50,000 cells, with each point averaging 10–24 spheroids) were obtained per biopsy, provid-
ing information on drug efficacy over time from the analysis of brightfield and fluorescence images.
Overall, this is the first example of an equipment-free, lab-on-a-chip platform enabling miniaturised com-
pound screening on 3D tumour models from biopsy tissue with a throughput that is 100-fold greater than any 
previously described for spheroids overall8,23–26. This novel approach offers an animal-free, practical solution to 
personalised drug screening of 3D tumour biopsy preparations.
Methods
Device design and fabrication. Multi-layered microfluidic devices were fabricated using standard soft- 
and photo-lithography techniques and consisted of two polydimethylsiloxane (PDMS) parts bonded together 
(Fig. 1). Briefly, both PDMS parts were replica moulds from photoresist-patterned silicon wafers. The wafers were 
fabricated by using SU-8-3035 and SU-8-3010 (3000 Series, MicroChem Corp.), according to the manufacturer’s 
protocol. Spin-coated resist was exposed to collimated UV light through a photomask (JD Photo-Tools, UK) 
and developed using MicroPosit EC solvent (Rohm and Haas, US). In order to prevent the adhesion of PDMS 
to the patterned silicon wafer, 1 H,1 H,2 H,2H-perfluorooctyl-trichlorosilane (Sigma Aldrich, UK) was applied 
by vapour deposition (45 minutes) to each wafer. To fabricate devices, PDMS prepolymer (Sylgard 184, Dow 
Corning) was mixed with curing agent in a 10:1 ratio, poured on the patterned wafers and cured at 85 °C for at 
least 2 hours. To create an approximately flat and uniformly thick (~1 mm) bottom PDMS layer, plastic spacers 
and a glass slide were coated with 0.1% hydroxymethylcellulose (HPMC, Sigma) to prevent PDMS adhesion. The 
spacers were placed on the wafer prior to pouring PDMS, then the glass slide was placed on top of the spacers and 
secured to the wafers using metal clamps. Once cured, PDMS devices were peeled from the moulds, cut to size 
and open wells were created using a surgical biopsy punch (4 or 8 mm diameter, Miltex). The PDMS layers were 
then cleaned and permanently bonded together using oxygen plasma surface treatment (Pico plasma cleaner, 
Diener electronic). Bonded devices were then baked at 85 °C for at least 30 minutes and stored dry. Prior to cell 
seeding, the devices were exposed to oxygen plasma for 2 minutes and a surfactant solution of 1% Synperonic 
F108 (Sigma-Aldrich, UK) in deionised water was immediately pipetted into the device to render the PDMS 
inner channel surfaces non-adherent and biocompatible. The devices were incubated at 37 °C and 5% CO2 for 
24 hours. The remaining surfactant solution was then removed by washing the device with phosphate buffered 
saline (Fisher Scientific), followed by injection of incomplete medium.
Cell culture. Human high-grade glioma cells (UVW) were provided by Dr Marie Boyd (University of 
Strathclyde). UVW cells and spheroids were maintained at 37 °C and 5% CO2 in minimum essential medium 
(Gibco), supplemented with 10% fetal bovine serum (Gibco), 2.5 μg ml−1 Fungizone (Gibco), 100 U ml−1 
Penicillin/Streptomycin (Gibco) and 2 mmol l−1 L-Glutamine (Gibco). LNCaP cells were provided by Prof. Hing 
Leung (University of Glasgow) and were maintained at 37 °C and 5% CO2 in RPMI-1640 supplemented with 10% 
fetal bovine serum (Gibco), 2.5 μg ml−1 Fungizone (Gibco), 100 U ml−1 Penicillin/Streptomycin (Gibco), 1 mmol 
l-1 Sodium pyruvate (ThermoFisher) and 2 mmol l−1 L-Glutamine (Gibco).
Human prostate samples were obtained from patients undergoing transrectal ultrasound (TRUS) biopsy for 
investigation of prostate cancer and cultured using a simple, previously optimised, 2D culture method. Samples 
were stored in a serum-free RPMI (Invitrogen, UK) at 4 °C overnight. Biopsies were then minced and suspended 
in serum-free RPMI and incubated at 37 °C in 5% CO2 overnight. A cell strainer was used to remove any single 
cells, including fibroblasts, from the tissue pieces. The tissue pieces were washed three times in 10 ml of PBS 
(Invitrogen, UK). The remaining tissue pieces were re-suspended in 5 ml of primary prostate cell media, contain-
ing a range of supplements to enhance epithelial growth and reduce fibroblast populations (Table S1 in SI). The 
tissue pieced were cultured in a T-25 Matrigel-coated flask at 37 °C in 5% CO2, left undisturbed for 7 days to allow 
attachment of the cells/tissue pieces to the flask. Media was renewed after 7 days, and every 2–3 days thereafter. 
Cells were passaged at approximately 70% confluency to maintain a monolayer and prevent overcrowding. Cells 
were then washed twice in PBS heated to 37 °C to remove any traces of media. Cells were incubated in 3 ml of 
trypsin (Invitrogen, UK) for 5 minutes in 5% CO2 at 37 °C. Once cells were detached from the flask, they were 
washed three times in PBS. Finally, the cells were re-suspended in 10 ml of primary prostate cell media and cul-
tured in a T-75 flask at 37 °C in 5% CO2. Again, cells were cultured to approximately 70% confluency before being 
passaged 1:4 into four T75 flasks. Prior to microfluidic experiments, cells were detached from the bottom of T75 
culture flasks (Corning) using 0.25% Trypsin-EDTA (Gibco), dead cells excluded using Trypan Blue (Gibco) and 
cell suspensions were prepared in complete medium. One flask was kept for spheroid formation in microfluidic 
devices and remaining flasks were used for characterisation by RT-qPCR.
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Ethical approval and informed consent. All methods involving the use of human tissue samples were 
carried out in accordance with relevant guidelines and regulations. All relevant regulatory approvals required for 
the use of anonymised human tissue and experimental protocols to conduct this work was obtained by the West 
of Scotland Research Ethics Service (ref. 16/WS/0015). Informed consent was obtained from all subjects.
RT-qPCR. RNA was extracted from biopsy preparations and cDNA synthesis was performed as detailed in 
SI. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was performed to allow comparison 
between gene expression in the control sample (PNT2 benign cell line) and the immortalised prostate cell lines 
and primary prostate cells. A 96 well optical fast PCR plate was used. The following quantities were added in each 
well: 40 ng cDNA from the cell line of interest, 10 μL of master mix (Life Technologies), 5 μL nuclease-free water 
and 1 μL of gene expression assay. The gene expression assays used in this study were all Taqman Gene Expression 
Assays and included predesigned primers and probes sets for the androgen receptor (AR), fatty acid synthase 
(FASN), kallikrein-3 (KLK-3 gene for the prostate specific antigen protein), golgi membrane protein 1 (GOLM1) 
and alpha-methylacyl-CoA racemase (AMACR) (Applied Biosystems, cat. no. Hs00171172_m1, Hs01005622_m1, 
Hs02576345_m1, Hs00213061_m1, and Hs01091292, respectively). Blank control wells containing only the mix-
ture and no cDNA were included in each plate to exclude contamination. Plates were sealed and centrifuged at 
1200 rpm for 3 minutes. Air bubbles were removed using a Microlance needle. RT-qPCR was performed using an 
ABI 7500 real time PCR machine (Applied Biosystems). Samples were heated at 50 °C for two minutes, 95 °C for 
10 minutes then 40 cycles of 95 °C for 15 seconds and 60 °C for one minute. Gene expression was normalised to 
the beta-actin (ActB) housekeeping gene (Applied Biosystems, cat. no. Hs01060665_g1). The comparative cycle 
threshold (ΔΔCt) method was used to quantify relative gene expression.
Figure 1. Microfluidic device layout and functions. (A) Schematic representation of the device structure, 
comprising a microchannel network and an array of square micro-wells, with a width of 150 µm and a 
depth of 180 µm. By seeding a single cell aggregate into the central channel, compact spheroids were formed 
over 48 hours. The microfluidic network enabled both to perfuse fresh medium, and to create a compound 
concentration gradient across the array. (B) Fluorescent image showing a calcein concentration gradient over 
the micro-well array. (C) Schematic cross-section of the gradient generated along a column of the spheroid 
array. (D) Representative images of spheroid size distribution obtained along rows and columns of the micro-
well array. (E) Example of prostate tumour biopsy-derived spheroids formed from a single cell suspension and 
subsequent culture in the micro-wells (vehicle control; brightfield images from day 0 to day 8; fluorescent image 
from viability stain on day8 using FDA (green) and PI (red)). Scale bars = 100 µm.
www.nature.com/scientificreports/
4SCIEntIfIC REPoRTS |  (2018) 8:14672  | DOI:10.1038/s41598-018-33055-0
Spheroid formation. Cells were seeded into the microfluidic devices as a single cell suspension. For UVW 
and LNCaP cells, 12 µL of cell suspension at a concentration of 7 × 106 cells/mL were pipetted into the inlet open 
well of the culture channel and sedimented at the bottom of the microwells of the spheroid array. For primary 
prostate cells, a cell suspension of 2 × 106 cells/mL was prepared and 12 µL were seeded into each device. Excess 
cells in the outlet wells were washed out. Due to the non-adherent condition of the inner channel surfaces, cells 
typically aggregated into compact multicellular spheroids within 48 hours. Medium was exchanged every 24 to 
48 hours, depending on the cell type used, using a micropipette.
Viability staining. Spheroid viability was assessed by using propidium iodide (PI, Sigma-Aldrich) at 
20 µg mL−1, fluorescein diacetate (FDA, Sigma-Aldrich) at 8 µg mL−1 and Hoechst33324 at 5 µmol L−1 (Thermo 
Scientific). Spheroids were incubated with the dyes in the microfluidics for 15 minutes at room temperature. 
Excess dye was then washed off using PBS for 5 minutes and spheroids were imaged immediately. After staining, 
experiments were terminated.
Microfluidic drug screening. A 1.6 mmol L−1 stock solution of cisplatin (Sigma-Aldrich) was produced by 
dissolving cisplatin in 0.9% NaCl solution (Sigma-Aldrich) and stored at 4 °C for up to 30 days. A 10 mmol L−1 
stock solution of Docetaxel (Selleckchem) and a 10 mmol L−1 solution of Enzalutamide in DMSO (Selleckchem) 
was stored at −20 °C. All working drug solutions were prepared in complete medium and used immediately.
Spheroids were formed and initially cultured in the microfluidics for 3–5 days. Subsequently, all medium 
was removed from the devices and replaced by either a drug solution in single channel devices (for comparison 
against results from drug gradient generating devices) or by both fresh medium and a drug solution in the gra-
dient generating devices. Drugs were left to incubate in the devices for 12 hours at 37 °C and 5% CO2. Drug solu-
tions were then washed out using complete medium and spheroid responses were monitored for at least 3 days 
(and up to 14 days) post drug exposure using brightfield and epifluorescence microscopy. Control experiments 
were performed for each cell line and biopsy culture and for different set of experiments. Concentration ranges 
for each drug were obtained from the literature, when available for 3D models, or modified from 2D derived data.
Calcein gradient generation. To characterise the formation of a microfluidic compound concentration 
gradient, calcein was used to image the temporal evolution of the gradient via epifluorescence microscopy. 
Calcein (Sigma-Aldrich) was dissolved in deionised water to produce a 100 µM solution and used in place of 
a drug, following the developed protocols. Fluorescent images were acquired using an inverted microscope 
(Axiovert A1, Zeiss) and a CMOS camera (Orca Flash 4.0, Hamamatsu) over 16 hours. Devices were kept in high 
humidity conditions inside a microscope stage incubator (Tokai Hit INUB-WELS-F1, Japan) during time-lapse 
recording.
Numerical simulation. To estimate the temporal evolution of the hydrostatic pressure values within each 
open well of the device during compound concentration gradient formation, numerical and analytical models 
of the fluid behaviour in the device were developed. First, an equivalent electrical circuit of the microfluidic 
device structure was created using Orcad PSpice, where a distributed resistive network represented the micro-
fluidic channel network and capacitors represented the open well reservoirs (Fig. S1 in SI). The initial conditions 
(amount of electrical charge in each capacitor) were set to represent the starting volume of fluids in each well at 
the start of the experiment. Values of equivalent electrical resistance and capacitance were calculated as previously 
described27,28. Following this, an analytical expression of the hydrostatic pressure was derived using a simplified 
equivalent electric circuit (Fig. S2 in SI) and used as an input for finite element model (FEM) simulation. To 
estimate the temporal evolution of microfluidic compound concentration gradients, a 3D FEM model of the 
microfluidic device was built using COMSOL 3.5 (Fig. S3A,B in SI). The Navier–Stokes equations were solved 
to model pressure-driven fluid transport alongside Fick’s law equations to model the compound diffusive trans-
port. Diffusion coefficients were obtained from the literature when possible or estimated from the compound 
molecular weight and adjusted according to experimental conditions. The microfluidic concentration gradient 
obtained from the simulation (Fig. S3C in SI) was compared against experimental results using calcein (Fig. 2C) 
showing good accuracy of the numerical model (Fig. S3D). Simulations for all compounds tested were carried out 
to estimate variation in the compound concentration gradient due to different diffusion coefficients (estimated in 
a range 0.2–0.8 × 10−10 m2 s−1).
Microscopy and image analysis. Spheroids were monitored every 24–48 hours using an inverted micro-
scope (Observer A1, Zeiss) connected to an Orca Flash 4.0 camera (Hamamatsu). For long-term live-cell imaging, 
a microscope stage incubator (Tokai Hit INUB-WELS-F1, Japan) was used to maintain high humidity condition 
whilst keeping the device at 37 °C and 5% CO2. Images were analysed and data processed using ZEN Blue, Fiji29 
and Matlab R2014b. In-house developed Matlab routines were used to extract spheroid area and perimeter from 
the brightfield images, as well as spheroid areas and dye intensity from the fluorescent images.
Screening assay readouts. In addition to providing semi-quantitative information of drug efficacy using 
live-dead staining (Fig. 2D), the brightfield image of each spheroid was processed to estimate its health using a 
shape factor parameter, SF, described by the following equation:
π
=S P
A4
, (1)F
2
where P is the perimeter (P = 2πr) and A (A = πr2) is the area of the spheroid, respectively. Whilst healthy 
spheroids maintained a smooth perimeter and a spherical outline (R ~ 1), unhealthy spheroids showed sign of 
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disaggregation and a rougher outline (R > 1) that was directly proportional to the drug concentration used. Such 
a level of disaggregation was quantified utilising equation (1)13,30,31 (Fig. 3B). Additionally, as a measure of drug 
efficacy, the viable fraction, VF, was calculated by processing fluorescent images in combination with brightfield 
images using equation (2):
=V Area
Area _
,
(2)F
FDA
BF PtD
where AreaFDA is the area of the spheroid extracted from the fluorescent image from the FDA staining, represent-
ing the area of the spheroid that is assumed viable. AreaBF_PtD is the area of the spheroid, prior to drug incubation, 
extracted from the brightfield image. Values of VF ≥ 1 indicate a spheroid that has either grown over time or has 
remained unaffected by the treatment with respect to its healthy state prior to drug incubation, whilst VF < 1 
indicates a detrimental effect of the drug or an unhealthy spheroid.
Statistical analysis. Graphpad Prism 7 was used for plotting data and for statistical analysis. All data is 
presented as mean ± standard error of the mean, using bar graphs or scatter plots with sigmoidal fitting. Results 
were compared using two-way ANOVA tests, with differences considered significant when P < 0.05. The Pearson 
correlation coefficient was calculated using Graphpad Prism 7.
Results
Device structure and spheroid culture. The microfluidic device structure is composed of two layers: a 
bottom layer (~1 mm thick PDMS part), containing an array of 240 square micro-wells (150 × 150 × 180 µm), was 
used for spheroid formation and subsequent culture; a top layer (~5 mm thick PDMS part) containing a network 
of microchannels and accessible via open wells, was designed for cell injection, medium perfusion and drug 
gradient formation. In the top layer, two side channels (35 µm depth) were connected to a central channel (con-
taining the micro-wells) by an array of smaller microchannels (7 µm depth) (Fig. 1C). First, a cell suspension was 
injected in one of the central wells (W3–4 in Fig. 1A), creating a flow along the central channel that allowed cells 
to sediment into the micro-wells, as previously reported32,33. Due to the non-adherent conditions of the micro-
wells, single cells formed a compact multicellular spheroid within 2 days of culture (Video S1 in SI). The seeding 
protocol resulted in a decreasing number of cells seeded in each column of the micro-well array, creating a range 
of spheroid sizes (50–150 µm) that could be tested simultaneously (Fig. 1D).
Figure 2. Overflow ports enabled the formation of long-lasting chemical concentration gradients without 
external fluid flow actuation. (A,B) Schematic illustration and temporal evolution of the hydrostatic pressure 
difference ΔP(h) for the same microfluidic device in the absence (A) and presence (B) of overflow ports. (C) 
Plot of the mean fluorescent intensity of all the wells in a row of the spheroid array obtained using calcein 
(100 µM) to visualize the formation of a stable concentration gradient lasting for over 15 hours (Video S2 in SI). 
Error bars represent standard error of the mean and show the variability between wells in each row. (D) Overlay 
epifluorescence microscopy image of live/dead staining (green = FDA, red = PI) of UVW glioma spheroids 
following a cisplatin concentration gradient for 12 hours. Scale bar is 500 µm.
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Subsequently, by creating a hydrostatic pressure difference between the external (W1–2–5–6 in Fig. 1A) and 
the central reservoirs (W3–4 in Fig. 1A), an exponentially decaying flow was created over the spheroid array in 
the central channel, which had two purposes. First, it was used to facilitate continuous medium exchange (every 
24–48 hours) without applying shear stress to the spheroids, as well as removing waste products. Using this pro-
tocol, spheroids were cultured in the devices for up to 21 days when using cell lines, and up to 12 days when 
culturing biopsy-derived primary cells (Fig. 1E). Second, it could be used to create a stable, long-lasting drug 
concentration gradient (Fig. 1B) across the spheroid array without the need of external instrumentation. As a 
result, all the spheroids in the same row were exposed to the same concentration, whilst an almost linear concen-
tration gradient was achieved along the columns of the micro-well array (Fig. 1B,C). The latter feature provided 
the means for obtaining an 8-point concentration response curve per device, where each point is the mean of the 
readouts of all the spheroids belonging to the same row and allowing for the required spheroid size to be selected.
Long-lasting self-generated compound concentration gradients. To generate a chemical concen-
tration gradient in the central channel, a near steady-state flow must be maintained, compensating for molecular 
diffusion across the spheroid array. In the absence of external equipment, this was achieved by carefully designing 
the resistive and capacitive microfluidic network and by creating overflow ports in both reservoirs connected to 
the central channel (W3–4 in Fig. 1A). To create the concentration gradient, a volume of a drug solution was pipet-
ted into the reservoirs of a side channel (W1–2 in Fig. 1A) and the same volume of complete medium was pipetted 
Figure 3. Screening readouts. (A) Temporal evolution of the average shape factor, SF, in each row of the 
spheroid array when using UVW cells. Each row was exposed to a decreasing concentration of cisplatin for 
12 hours (as estimated from the numerical simulation), from 206.5 µM (Row 1) to 42.2 µM (Row 8). Inserts 
show brightfield and fluorescent images of representative spheroids prior to drug application (day 5)  
and after viability staining (day 8, red = PI, green = FDA) for different positions in the array. (B) 8-point 
concentration response curves obtained from data analysis averaging outcomes from each row of the spheroid 
array using UVW and cisplatin (n = 24). Both viable fraction, VF, and shape factor, SF, are plotted for the 
two spheroid size groups analysed: Group 1 = 0–75 µm and Group 2 = 76–150 µm. EC50 VF Group 1 = 181.5 µM, 
EC50 VF Group2 = 98.9 µM, EC50 SF Group1 = 183.5 µM, EC50 SF Group2 = 121.8 µM. (C) Comparison between 8-point 
concentration response curves obtained by exposing UVW spheroids to cisplatin and LNCaP spheroids to 
docetaxel in gradient devices for 12 hours. Both viable fraction, VF, and shape factor, SF, curves are plotted 
for all the spheroids in the array. Values are shown as mean (of n = 24 spheroids) ± standard error of the 
mean. (D) Representative brightfield and fluorescent images obtained from UVW-cisplatin (day 5 and 8) and 
LNCaP-docetaxel experiments in gradient devices (day 3 and 8), confirming successful gradient formation and 
consequent drug effects.
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into the reservoirs of the other side channel (W5–6 in Fig. 1A), whilst both reservoirs of the central channel con-
tained a smaller volume of complete medium. This created a symmetrical hydrostatic pressure-driven flow across 
the micro-well array that simultaneously transported drug solution and medium from each side channel, respec-
tively, towards the reservoirs of the central channel. The hydrostatic pressure difference, ΔP = (P(CS) − P(CC)), 
between the side reservoirs and central reservoirs of the microfluidic network followed an exponential decay over 
time (Fig. 2). This was primarily dependent on the fluid height (h) in each reservoir (hydrostatic pressure being 
P = ρgh, ρ is the fluid density and g the gravitational constant) and determined the magnitude of the flow rate 
in the central channel (ΔP = RQ, where R is the fluidic resistance of the channel network and Q the volumetric 
flow rate). In the absence of overflow ports (Fig. 2A), the liquid level between inlet and outlet would eventually 
equilibrate due to a decreasing P(CS) and an increasing P(CC). Conversely, when overflow ports were created in 
the central reservoirs (Fig. 2B), P(CC) remained constant after the fluid volume had reached the height of the 
overflow port, whilst the liquid level in the side reservoirs decreased to the fluid level of the central reservoirs. 
Consequently, the rate of change of ΔP decreased considerably faster in the absence of an overflow, leading to a 
quick decrease of the flow rate in the central channel, which prevented a concentration gradient to be maintained 
for longer time periods. Therefore, the introduction of overflow ports and an appropriate microfluidic design 
allowed fine-tuning of the flow in the central channel to compensate for molecular diffusion, thus achieving a 
long-lasting concentration gradient (Fig. 2B).
In order to estimate the volumetric flow rates within the microchannel and chamber network, an analogous 
electrical circuit of the microfluidic network was created27, where reservoirs were considered as electrical capacitors 
and the microchannel network as an electrical resistive mesh. This circuit was simulated in PSpice (Fig. S1 in SI) 
to estimate the hydrostatic pressure patterns in each reservoir and a simplified analytical model (Fig. S2 in SI) was 
derived, leading to the following set of equations:
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where P(CS) and P(CC) are the respective hydrostatic pressure values as a function of time; hsin and hCin are the initial fluid height values in the side and central well reservoirs, respectively; RT is the device fluidic resistive net-
work (Fig. S2 in SI) and AS and AC are the area of circular side and central well reservoirs, respectively.
Finally, a finite element method (FEM) numerical model (Comsol Multiphysics 3.5) was used to estimate 
the convective and diffusive behaviour of the compound of choice. To validate the models developed, calcein 
(100 µM) was used to experimentally visualise the formation and duration of the microfluidic gradient using 
time-lapse epifluorescence microscopy. The results (Fig. 2C) were compared to the numerical simulation 
(Fig. S2C,D in SI), demonstrating the suitability of this approach and the robustness of the numerical model. 
Subsequently, diffusion coefficients for each compound used were estimated or obtained from the literature and 
simulations were run to identify the appropriate protocols for each compound. Prior to biopsy analysis, experi-
mental validation of the platform was performed using cell lines (Fig. 2D).
Cancer drug screening assay validation. Cisplatin, a chemotherapeutic agent used in the clinic against 
a broad range of solid tumours13,34, was used on UVW spheroids for the validation of the microfluidic drug 
screening assay. UVW spheroids were formed as detailed above and cultured for 5 days prior to the formation 
of a cisplatin concentration gradient (29–184 µM) in the device (performed in triplicates). In contrast to micro-
fluidic systems operated using external equipment23,24, such as syringe pumps, cells seeded with a hydrostatic 
pressure-driven flow resulted in a progressively decreasing number of cells entering the micro-wells that were 
further away from the inlet reservoir. Further, since cells are seeded from both sides of the cell culture channel 
(see W3 & W4, Fig. 1A) this cumulative effect is seen on both ends of the microwell array. This led to the formation 
of spheroids with a range of sizes (>90% within the range 50–100 µm in diameter, see Fig. S4B in SI), an outcome 
that was exploited to assess spheroid size-dependent drug effects. It is worth noting, that whilst a range of sphe-
roid sizes were generated in each row, the variation between rows remained small (Fig. S4A in SI). An almost even 
distribution of cells in microwells could be achieved by utilising syringe pumps23, which can provide a constant 
velocity.
Drug incubation was maintained for at least 12 hours, whilst devices were kept in an incubator. Drug concen-
tration values were estimated using the numerical simulations for each row of the gradient device. Subsequently, 
the drug was removed from the device in order to avoid cross-contamination over the spheroid array. Finally, 
on day 8, spheroid viability was assessed by staining using PI and FDA and the experiments were terminated. 
Both brightfield and fluorescence images of the spheroids were processed to calculate the temporal evolution of 
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the shape factor (equation (1), Fig. 3A), as well as the viable fraction (equation (2)) on day 8 (Fig. 3B). Viability 
dyes were only used as end-point measurements due to their potential cytotoxic effects, whereas the additional 
readout of the shape factor enabled continuous assessment of spheroid health (extracted from daily brightfield 
images), revealing both short- and long-term drug effects. The shape factor increased after cisplatin incubation 
in a concentration-dependent manner, with statistically significant increases (p < 0.001) occurring at concentra-
tions ≥ 93.2 µM (Fig. 3A). Concentrations of cisplatin ≥ 159.8 µM produced a significant increase (p < 0.001) in 
the shape factor 24 hours after drug application, whilst for concentrations (93.2–124.3 µM), the shape factor only 
increased significantly 3 days post drug application.
Two spheroid groups were arbitrarily created, based on spheroid diameter (Group 1 = 0–75 µm, Group 
2 = 76–150 µm) (Fig. 3B), to investigate size-dependent drug effects. EC50 values, defined as the concentration 
of a drug that produces half of its maximum response, were calculated from both brightfield and fluorescent 
images. Parallel experiments were carried out in triplicates, using just the central chamber of the device, with 
each device containing a single known drug concentration (0, 29.4, 71.5, 101.2, 155.5, 183.7 µM, respectively) to 
validate the results obtained from the gradient-generating device. IC50 values obtained from these experiments 
matched results from the gradient device experiments (EC50 Fixed concentration = 103.1 µM, EC50 Gradient 
device = 103.7 µM, Fig. S4 in SI), confirming the robustness of the numerical model and experimental proto-
cols developed. Additionally, experiments were performed using the prostate cancer cell line, LNCaP, which was 
exposed to a concentration gradient of docetaxel (Fig. 3C,D). For both UVW and LNCaP cells, results confirmed 
the successful formation of a concentration gradient over the spheroid array. The viable fraction parameter proved 
to be a robust readout for both assays. However, in the case of LNCaP spheroids, the administration of docetaxel 
resulted in a reduction of spheroid size with increasing concentration, rather than increased spheroid disaggrega-
tion. Consequently, the shape factor did not vary significantly as was observed in the case of UVW spheroids and 
cisplatin. To further investigate the use of the shape factor as a readout for spheroid health, correlation analysis 
was conducted using the Pearson correlation coefficient as described by Thakuri et al.35 to quantify the correlation 
between the shape factor and the viable fraction. We observed a strong negative correlation between the viable 
fraction and the spheroid shape factor, with a correlation coefficient of −0.9333 in the case of the UVW spheroids 
(Fig. 3C,D). This suggests that, as the viable fraction of a spheroid decreases, its shape factor will increase in a 
highly correlative manner. This corresponds with our observations and the images shown in Fig. 3D. However, 
in the case of LnCAP cells shown in Fig. 3C, the correlation coefficient did not suggest a correlation, since these 
spheroids decreased in size after drug exposure, but remained structurally intact.
Prostate tumour biopsy screening. Primary prostate cancer tissue from two different patient biopsies 
was cultured for two weeks prior to microfluidic experiments. Morphological assessment of the expanded biop-
sies was conducted to assess the presence of multiple cell types in each culture. From each biopsy preparation, 
a cancer-cell enriched single-cell suspension was used to prepare a number of gradient-generating devices. 
Depending on the tissue proliferation during expansion, between 13 and 22 devices could be seeded per biopsy. 
Alongside the microfluidic experiments, RT-qPCR was performed for each biopsy to assess the presence of pros-
tate cancer cells and several prostate cancer biomarkers: androgen receptors (ARs), prostate-specific androgen 
(KLK3) and alpha-methyl-acyl-CoA racemase (AMACR). Expression of these markers was quantified using a 
benign prostate cell line (PNT2) as a reference and a prostate cancer cell line (LNCaP, Fig. 4D) for comparison. 
Pathology reports confirmed that both patients in the study had prostate cancer. Spheroids were allowed to form 
in the microfluidic device for 3 days in all experiments, before each condition was tested in triplicates. To demon-
strate the capabilities of the microfluidic platform, different proof-of-concept experiments were carried out for 
each biopsy.
Using cells derived from Patient 1, fractionated chemotherapy was mimicked, by applying a number of drugs 
(enzalutamide, docetaxel or cisplatin), each drug being a separate experiment. On day 3 of culture, a drug gradi-
ent (8.9–108.8 µM docetaxel, 14–92 µM enzalutamide or 21.1–103.2 µM cisplatin) was applied to the spheroids 
for 12 hours. After drug removal, spheroids were monitored daily using brightfield microscopy until day 8. In a 
number of devices (a mixture of devices either with 8 rows of 150 um well or 5 rows of 250 um wells) spheroid 
viability was determined on day 8 by staining with PI and FDA (Fig. 4B). In the remaining devices, a second drug 
gradient was reapplied for 12 hours (for all conditions tested), doubling the concentration ranges (17.8–217.6 µM 
docetaxel, 29.4–183.7 µM enzalutamide and 42.2–206.5 µM cisplatin). Monitoring continued until day 12, when 
viability was measured using FDA and PI (Fig. 4B). Following the first drug application, viability staining showed 
100% viability across the entire concentration range for all drugs (Fig. S5A). However, for docetaxel, a tran-
sient increase (p = 0.049) in shape factor was observed on day 4 for the highest concentration applied (108.8 µM, 
Fig. 4A, Row 1). Following the second drug application, docetaxel produced an increase (p < 0.001) in shape 
factor for concentrations ≥ 122.1 µM, with viability staining following a similar trend, resulting in an EC50_Patient 1 
= 161.7 µM. RT-qPCR results indicated elevated expression of all markers in LNCaP cells with respect to PNT2 
cells. Further, the increased expression of AR, KLK3 and AMACR in Patient 1 and 2 suggests the presence of 
prostate cancer cells within the mixed biopsy population.
To confirm the robustness of the protocol, the same higher concentrations of drugs were tested on sphe-
roids derived from the biopsy preparation of Patient 2. Following cell seeding, concentration gradients of several 
drugs were applied on day 3 of culture (docetaxel, enzalutamide ± DHT enzalutamide in a range 29.4–183.7 µM). 
On day 8, viability staining was conducted in all devices and experiments were terminated. Out of all condi-
tions tested, only docetaxel produced a detrimental effect to the spheroids, with similar concentration-response 
curves and EC50 values as seen for Patient 1 (EC50_Patient 1 = 161.7 µM, EC50_Patient 2 = 165.2 µM, Fig. 4B). In order 
to compare spheroid responses between the two patients, only spheroids with a similar diameter were considered 
(25–95 µm diameter, Fig. 4C).
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Discussion
Our approach provides a novel microfluidic solution for self-generating drug concentration gradients across 
hundreds of multicellular spheroids in a shear stress-free manner without the need of external fluid actuation. 
We have demonstrated that a concentration gradient remained stable for 12–16 hours (Fig. 2C,D). These concen-
tration gradients can be re-established over time, a feature that was utilised here to mimic fractionated chemo-
therapy and that, alternatively, could be used to create extended, continuous drug incubation in multiples of 
12–16 hours with the current device layout.
When the compound of interest cannot be visualised via microscopy (most anticancer agents are 
non-fluorescent), it is important to assure that the expected gradient pattern has occurred. The validated numer-
ical models developed (Eq. 3) describe the temporal evolution of the fluid volumes in all wells. When compared 
to the experimental values, they provide a good measure of whether the gradient had developed as expected. 
Therefore, in all our experiments, once a concentration gradient had been applied for 12 hours, measurement 
of the remaining liquid volumes in each reservoir provided indication of successful device operation. If the liq-
uid volumes in the reservoirs differed >10% from the expected value, the experiment was discarded. This proce-
dure served to detect whether external factors, which were not included in the simulation, such as the formation 
of a liquid meniscus in the overflow ports or excessive evaporation in the reservoirs, compromised the device 
operation. Our 3D FEM simulation estimated that, in the worst-case scenario, ~10% change in the gradient con-
centration pattern could occur over 24 hours. Further, once the gradient has been established, minor variation in 
concentration can occur across the wells belonging to the same row (Fig. S3 and Video S2) due to fringe effects, 
especially in rows 1 and 2. However, this error was negligible (<1%) in the majority of rows according to our 
experiments with calcein. To account for potential variations, spheroids positioned in the first and last three col-
umns of the array were excluded from the analysis. Overall, due to the external factors identified above, a 13-hour 
Figure 4. Primary prostate biopsy experiment results. (A) Shape factor temporal evolution obtained averaging 
all the spheroid responses in the highest (Row1), middle (Row4&6) and lowest (Row8) concentration of 
docetaxel in the case of repeated drug application (only four rows were plotted for clarity). *Represent p < 0.05. 
(B) Representative images from fractionated chemotherapy experiments. From left to right: bright-field (day 
3, prior to the first drug incubation) and fluorescent (day 8, experiment terminated) images of biopsy derived 
spheroids from Patient 1 from one set of 11 devices. No detrimental effect was apparent on day 8; bright-field 
(day 8 prior to the second drug incubation) and fluorescent (day 12, experiment terminated) images of biopsy 
derived spheroids from Patient 1 from a second set of 11 devices. A concentration-dependent detrimental effect 
due to docetaxel application was apparent on day 12. (C) Comparison between concentration response curves 
obtained from Patient 1 and Patient 2 derived spheroids using the shape factor for a selection of drugs tested. 
Only docetaxel produced a significant increase in cell death for both patients at the highest concentrations.  
(D) RT q-PCR validation of the presence of prostate cancer cells within the cultured cells, using expression of 
AR, KLK3 and AMACR. PNT2 cells served as reference group and ActinB as a housekeeping gene. Values are 
fold change ± standard error.
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window (1 hour for gradient establishment and 12 hours of drug incubation, Fig. 2C) was selected to prevent 
unwanted effects. Further, improvement to the fabrication procedures (e.g. by using injection moulding) and 
replacement of PDMS (e.g. in favour of polystyrene) are expected to greatly diminish the impact of surface treat-
ment, evaporation and liquid absorption into bulk PDMS, thus extending the duration of the chemical gradient.
Once established, the microfluidic gradient generates concentrations spanning two orders of magnitude (e.g. 
29.4–183.7 µM, Fig. 4C). With respect to typical drug screening in 2D (spanning both nanomolar and micro-
molar concentrations), this concentration range is restricted. However, a range of two orders of magnitude is 
frequently sufficient, since it is well documented that spheroids, derived either from cell lines or primary tissue, 
are more resistant to chemotherapeutic agents than cell monolayers. Hence, the use of an extended concentration 
range is not warranted. The concentration values of docetaxel, enzalutamide and cisplatin used in this work are 
in agreement with previous studies, which also suggested limited drug sensitivity to lower concentrations8,36,37. 
Additionally, when screening patient derived tissue, it becomes a priority to identify which drug or combination 
of drugs are affecting the spheroids in order to inform on the therapeutic approach most suited. In these condi-
tions, maximising the number of tests performed over the larger number of spheroids (due to the heterogeneity 
of the tissue) becomes predominant over the identification of an EC50 value. Finally, although the majority of 
our experiments were performed using a spheroid array comprising 8 rows of square wells of 150 µm size, we also 
carried out experiments when screening biopsy tissue using arrays comprising 5 rows of square wells of 250 µm 
size (Fig. S6) to account for screening larger spheroids. With the current design layout for gradient formation, this 
identified a trade-off between the number of points per curve against the spheroid size which could be an impor-
tant parameter when studying drug effects. In the future, the cell culture channel could be widened to increase 
the number of concentration points (i.e. obtaining further rows). However, while one could argue that the lower 
drug concentration in the array could act as a control line, an independent separate device would have to be used 
for control experiments.
The ability to culture a range of spheroid sizes within the device allows us to detect potential size-dependent 
drug effects. For example, Fig. 3B shows a size dependent response from UVW spheroids treated with cisplatin, 
where both shape factor and viable fraction vary depending on spheroid diameter. EC50 values obtained from 
both readouts indicate that larger spheroids were more sensitive to cisplatin than smaller ones. This deserves fur-
ther investigation but could be related to the presence of hypoxic cells in larger spheroids, which has been shown 
to increase the effectiveness of cisplatin in some cell lines38.
The heterogeneous nature of the tissue from a tumour biopsy, whilst ultimately an advantage for represent-
ing the real tumour microenvironment, provides challenges in terms of the different cell types contained (e.g. 
prostate cells, fibroblasts and cancer associated fibroblasts) and the overall amounts of cancer cells. The media 
employed in the current experiments aimed to preferentially select for and promote epithelial cancer cell expan-
sion through the addition of multiple additives including Fibroblast Growth Factor 10 (FGF10) and reduce 
fibroblast growth using Cholera Toxin39,40. However, a small percentage of fibroblasts remained. In order to char-
acterise the cell population, RT-qPCR was performed. Results demonstrated that primary cultures expressed 
both AR and prostate-specific androgen (PSA), suggesting that the AR was functional (Fig. 4D). However, 
despite the presence of seemingly functional AR, no concentration of enzalutamide (29–184 µM), a nonsteroidal 
AR-antagonist and signalling inhibitor, tested in this study for both Patient 1 and 2, had any effect on viability or 
proliferation. This is similar to the observations made by Gao et al.41, who showed that the majority of organoids 
tested in their study were resistant to enzalutamide, and could be for a number of reasons. Firstly, it has been 
shown that mutations, resulting in structural changes in the AR, can mediate enzalutamide-resistance42,43. The 
majority of patients will eventually develop resistance to enzalutamide, in addition to significant occurrence 
of de novo resistance44,45. Secondly, the presence of fibroblasts in the spheroids might confer some degree of 
chemotherapy-protection, which is a well-documented occurrence46,47 and can appear in a broad range of can-
cers, including enzalutamide-resistance in prostate cancer48. Fibroblast-mediated resistance is one mechanism 
that could explain the high extent of resistance shown by the primary prostate spheroids to all drugs tested in 
this project. Several publications41,49 have shown the large range of possible drug responses that can be obtained 
from organoids, not only within the same cancer type, but even within the same patient. However, since only two 
patients were considered in this study, no larger assumptions can be made.
In addition to the advantages obtained from miniaturised microfluidic assays, the ability to use label-free 
readouts, such as the shape factor, is an extremely valuable tool to inform on drug effects. Spheroid diameter is a 
commonly used parameter to establish drug efficacy, but is not always reliable when spheroid integrity is compro-
mised50, which can occur after drug incubation or insufficient culture conditions. Our study has shown that the 
combination of a spheroid-based assay with image analysis of bright-field images, can provide a sensitive meas-
ure of spheroid response to a drug, as previously reported13,30,31,51–53. Since the shape factor is a non-destructive 
measure of spheroid integrity (compared to dye-based single end-point measurements), it can provide valuable 
additional insights into the evolution of spheroid health over time, both for drug and control experiments. If 
dyes were used for daily assessments, it would require at least one gradient device per condition to be termi-
nated every day, limiting the number of possible screens. This is demonstrated in Fig. 4A, where the application 
of 108.8 µM docetaxel (Row 1) caused a transient change in shape factor around day 4. In this particular case, 
if viability staining were the only readout available, no detrimental effect could have been detected on day 8. 
Further, as shown in Fig. 3A, spheroid disaggregation increased in all treatment groups for 3 days after treatment, 
which highlights the importance of identifying a suitable day for end-point analysis. However, it is worth noting 
that concentration-response curves generated from the shape factor and viable fraction (Fig. 3C) did not always 
match. This may be due to the cancer model used and the drug’s mechanism of action. Importantly, the ability to 
provide multiple readouts from continuous monitoring and image analysis strongly mitigates the risks of misin-
terpreting drug effects.
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Conclusion
There is an ongoing need to develop more predictive and rapid means of profiling cancer patients to allow strati-
fied and personalised medicine solutions. Current investigation of anticancer therapeutic relies heavily on animal 
models (involving procedures implanting cancerous tissue from a human tumour into an immune-deficient or 
genetically engineered mouse). These approaches are very resource-, time- and cost-intensive. Our microfluidic 
technology offers a new solution for extensive anticancer compound screening using 3D micro-tumour models 
generated from cancer patient biopsies. For this, we anticipate applications in the screening of tissue that is noto-
riously difficult to analyse due to very small size biopsies (e.g. oesophageal tumour biopsies and other tissues 
obtained by fine-needle aspiration). Remarkably, whilst combination therapy is an emerging treatment approach 
for many cancer types, in vitro combinatorial screening of patient-derived 3D spheroids remains challenging 
due to the large cell number required. Therefore, it is conceivable that our system and protocols, when applied to 
combination chemo- and radio-therapy, may offer new and cost-effective avenues to future personalised medi-
cine solutions.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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